Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.

VVY

Vivoryon Therapeut (VVY)

Vivoryon Therapeut
Date:
Sort by:
 Showing the most relevant articles for your search:EU:VVY
DateTimeSourceHeadlineSymbolCompany
07/09/20241:00AMGlobeNewswire Inc.Vivoryon Therapeutics N.V. to Host R&D Update Call on July 18, 2024 Focused on Progress in Kidney DiseaseEU:VVYVivoryon Therapeut
06/21/20249:00AMGlobeNewswire Inc.Vivoryon Therapeutics N.V. Reports Outcome of 2024 Annual General MeetingEU:VVYVivoryon Therapeut
05/23/20241:00AMGlobeNewswire Inc.Vivoryon Therapeutics N.V. Reports Q1 2024 Financial Results and New Data Reinforcing Strategic Focus in Kidney DiseaseEU:VVYVivoryon Therapeut
05/15/20241:00AMGlobeNewswire Inc.Vivoryon Therapeutics N.V. to Report Q1 2024 Financial Results and Operational Progress on May 23, 2024EU:VVYVivoryon Therapeut
05/08/20241:00AMGlobeNewswire Inc.Vivoryon Therapeutics N.V. to Hold its 2024 Annual General Meeting on June 21, 2024EU:VVYVivoryon Therapeut
04/24/20241:00AMGlobeNewswire Inc.Vivoryon Therapeutics N.V. Reports Full Year 2023 Financial Results and Provides Varoglutamstat and Strategic UpdatesEU:VVYVivoryon Therapeut
04/16/20241:00AMGlobeNewswire Inc.Vivoryon Therapeutics N.V. to Report Full Year 2023 Financial Results and Operational Progress on April 24, 2024EU:VVYVivoryon Therapeut
03/15/20242:00AMGlobeNewswire Inc.Vivoryon Therapeutics N.V. Announces Changes to Board CompositionEU:VVYVivoryon Therapeut
03/04/20241:00AMGlobeNewswire Inc.Vivoryon Therapeutics N.V. Provides Update on VIVIAD Phase 2b Study of Varoglutamstat in Early Alzheimer’s DiseaseEU:VVYVivoryon Therapeut
01/08/20241:00AMGlobeNewswire Inc.Vivoryon Therapeutics N.V. to Host Investor Meetings in January 2024EU:VVYVivoryon Therapeut
12/06/20231:00AMGlobeNewswire Inc.Vivoryon Therapeutics N.V. Reports Third Quarter 2023 Financial Results and Highlights Operational ProgressEU:VVYVivoryon Therapeut
11/28/20231:00AMGlobeNewswire Inc.Vivoryon Therapeutics N.V. to Report Q3 2023 Financial Results and Operational Progress on December 6, 2023EU:VVYVivoryon Therapeut
11/07/20231:00AMGlobeNewswire Inc.Vivoryon Therapeutics N.V. to Present at Upcoming Investor ConferenceEU:VVYVivoryon Therapeut
11/07/20231:00AMGlobeNewswire Inc.Vivoryon Therapeutics N.V. to Present at Upcoming Investor ConferenceEU:VVYVivoryon Therapeut
10/26/20231:00AMGlobeNewswire Inc.Vivoryon Therapeutics N.V. Provides Comprehensive Progress Report for Ongoing Varoglutamstat Clinical Program Following R&D Event and VIVA-MIND DSMB Dose DecisionEU:VVYVivoryon Therapeut
10/23/20231:00AMGlobeNewswire Inc.Vivoryon Therapeutics N.V. Reports Positive Outcome from Independent Data Safety Monitoring Board with Unanimous Decision for VIVA-MIND U.S. Study of Varoglutamstat in Alzheimer’s Disease to Proceed at Highest Investigated DoseEU:VVYVivoryon Therapeut
10/23/20231:00AMGlobeNewswire Inc.Vivoryon Therapeutics N.V. Reports Positive Outcome from Independent Data Safety Monitoring Board with Unanimous Decision for VIVA-MIND U.S. Study of Varoglutamstat in Alzheimer’s Disease to Proceed at Highest Investigated DoseEU:VVYVivoryon Therapeut
10/17/20239:32AMGlobeNewswire Inc.Vivoryon Therapeutics N.V. Shares Highlights from Virtual R&D Event with Key Opinion LeadersEU:VVYVivoryon Therapeut
10/17/20239:32AMGlobeNewswire Inc.Vivoryon Therapeutics N.V. Shares Highlights from Virtual R&D Event with Key Opinion LeadersEU:VVYVivoryon Therapeut
10/05/20231:00AMGlobeNewswire Inc.Vivoryon Therapeutics N.V. Announces Virtual R&D Event with Key Opinion Leaders and Upcoming Conference ParticipationEU:VVYVivoryon Therapeut
10/05/20231:00AMGlobeNewswire Inc.Vivoryon Therapeutics N.V. Announces Virtual R&D Event with Key Opinion Leaders and Upcoming Conference ParticipationEU:VVYVivoryon Therapeut
09/15/20237:57AMGlobeNewswire Inc.Vivoryon Therapeutics N.V. Extraordinary General Meeting Approved Appointment of New Executive Directors to the BoardEU:VVYVivoryon Therapeut
09/07/20231:00AMGlobeNewswire Inc.Vivoryon Therapeutics N.V. Reports H1 2023 Financial Results and Highlights Operational ProgressEU:VVYVivoryon Therapeut
08/31/20231:00AMGlobeNewswire Inc.Vivoryon Therapeutics N.V. to Report Half Year 2023 Financial Results and Operational Progress on September 07, 2023EU:VVYVivoryon Therapeut
08/04/20235:35PMGlobeNewswire Inc.Vivoryon Therapeutics N.V. Extraordinary General Meeting to Confirm New Executive Director Appointments to the Board, Being Held on September 15, 2023EU:VVYVivoryon Therapeut
08/04/20235:30PMGlobeNewswire Inc.Vivoryon Therapeutics N.V. Announces Proposed Appointment of Dr. Frank Weber as Chief Executive OfficerEU:VVYVivoryon Therapeut
07/16/20233:00AMGlobeNewswire Inc.Vivoryon Therapeutics N.V. Shares Clinical Development Update Highlighting Progress of N3pE-Amyloid-targeting Small Molecule Varoglutamstat in Alzheimer’s DiseaseEU:VVYVivoryon Therapeut
06/21/202312:02PMGlobeNewswire Inc.Vivoryon Therapeutics N.V. Reports Outcome of 2023 Annual General MeetingEU:VVYVivoryon Therapeut
06/15/202311:49AMGlobeNewswire Inc.Vivoryon Therapeutics N.V. Announces CEO Transition PlanEU:VVYVivoryon Therapeut
06/01/20231:00AMGlobeNewswire Inc.Vivoryon Therapeutics N.V. to Participate in Upcoming ConferencesEU:VVYVivoryon Therapeut
 Showing the most relevant articles for your search:EU:VVY